Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs.
Femasys has an expansive, internally-created intellectual property portfolio with over 130 patents issued globally for our products and product candidates.
Infertility Products and Product Candidates
Research
Preclinical
De Novo Clinical Study
Anticipated Milestones
- IDE approval achieved from FDA for redesign in October 2022
- Enrollment completion expected Q2 2023
Research
Preclinical
Approval
Infertility Products and Product Candidates
Research
Preclinical
Approval
Contraception Product Candidate
Research
Preclinical
PMA Clinical Studies
STAGE I
STAGE II
STAGE III
Contraception Product Candidate
Permanent Birth Control and Ultrasound Occlusion Confirmation
Research
Preclinical
PMA Clinical Studies
Anticipated Milestones
- Commence PMA clinical trial after combined IDE submission approval in Q1 2023
Biopsy Product
Research
Preclinical
Approval
Biopsy Product
Endocervical Tissue Sampler
Research
Preclinical
Approval
FemEMB™
Endometrial Biopsy
CE = European Commission
IDE = Investigational Device Exemption
FDA = Food and Drug Administration
PMA = Premarket approval
Infertility
FemaSeed®
FemaSeed is a novel solution in development for insemination that can be performed as a first-line therapeutic option. It would be the first and only directed approach designed to be more affordable than assisted reproduction, such as in vitro fertilization (IVF).
Femvue® | FemCath™
FemBloc®
FemBloc is in development as the first and only in-office approach to permanent birth control without the need for anesthesia or special equipment, which would make this nonsurgical option easy to incorporate into existing practices worldwide. With a potential to be less than half the total cost of a surgical tubal ligation, FemBloc enriches the physician’s practice. FemBloc also features the first and only ultrasound approach to confirm success 90 days after the procedure.
Other Products
FemCerv®
FemCerv is the first and only approach for comprehensive tissue sampling for the diagnosis of cervical cancer. We are marketing this diagnostic option alongside our other female-specific medical products to physicians’ offices.